When should LDL be retested?

The optimal timing for LDL retesting cannot be derived from the provided context, which focuses on DNA tests and their limitations. In evidence-based clinical practice, retesting intervals depend on baseline levels and cardiovascular risk. For patients on lipid-lowering therapy, guidelines (e.g., ESC/EAS) recommend retesting after 4–12 weeks to assess response, then every 3–12 months once stable. For individuals with borderline high LDL but low overall risk, annual retesting is common. Importantly, LDL alone is insufficient; non-fasting lipids, apolipoprotein B, and Lp(a) provide additional insight. The context does not support using direct-to-consumer genetic tests for guiding retesting intervals. Consumers should rely on physician-ordered lab work and established risk calculators. Evidence grade: practice (clinical guidelines). No specific sources from the provided context.